Inflammation and the Metabolic Syndrome in Psychosis

精神病患者的炎症与代谢综合征 摘要文本 代谢综合征(METS)是一系列与发育相关的代谢危险因素 动脉粥样硬化性心血管疾病的发病率和死亡率。甲状旁腺激素在患者中非常常见 患有精神病，心血管疾病是这一患者群体死亡的主要原因。这个 甲硫氨酸还与低度炎症状态有关。血白细胞(WBC)计数--甚至 在正常范围内--可作为炎症的标志。精神错乱与增多有关 炎症，包括白细胞总数和分类计数增加。低密度脂蛋白的不良代谢效应 非典型抗精神病药物会增加甲状旁腺素的风险，可能会加剧血液中异常水平的炎症 记号笔。几个基于人群的大型样本发现，白细胞总数和分类计数是 与大都会运动队的风险及其个别标准有关。与一般人口相比，相对较少 已知炎症和精神错乱中的甲硫氨酸之间的联系，特别是基线 炎症标志物水平预测抗精神病药物治疗的代谢不良反应。这 应用程序解决了这些重要的知识差距。主要目标是执行系统化的 炎症与甲型肝炎流行和发病关系的综述和荟萃分析 精神病患者，包括精神分裂症开放翻译科学未发表的数据 (光学)项目，这是扬森和NIMH之间的一项开放科学倡议。此R03应用程序：1)具有 目标与NIMH对临床有用的生物标记物的战略重点一致，这些生物标记物可以预测 疾病轨迹，2)是一项严格设计的系统回顾和荟萃分析，使用未发表的数据 从光学项目中研究一种新的潜在生物标记物，该标记物可能在治疗前识别- 精神病患者发生抗精神病药物不良心脏代谢反应的风险增加，以及 代表着为这些患者提供个性化医疗方法的“下一步”，以及3)支持 将L30和K23获奖者的职业生涯过渡到R系列调查员，与NIH的Next保持一致 世代研究人员倡议。

INFLAMMATION AND THE METABOLIC SYNDROME IN PSYCHOSIS ABSTRACT TEXT The metabolic syndrome (MetS) is a constellation of metabolic risk factors associated with the development of atherosclerotic cardiovascular disease morbidity and mortality. The MetS is highly common in patients with psychosis, and cardiovascular disease is the leading cause of mortality in this patient population. The MetS is also associated with a state of low-grade inflammation. Blood white blood cell (WBC) counts—even within the normal range—serve as a marker of inflammation. Psychosis is associated with increased inflammation, including increased total and differential WBC counts. The adverse metabolic effects of atypical antipsychotics, which increase MetS risk, may potentiate aberrant levels of blood inflammatory markers. Several large population-based samples found that total and differential WBC counts were associated with risk of the MetS and its individual criteria. Compared to the general population, relatively less is known about associations between inflammation and the MetS in psychosis, especially whether baseline levels of inflammatory markers predict incident metabolic adverse effects of antipsychotic treatment. This application addresses these important knowledge gaps. The primary goals are to perform systematic reviews and meta-analyses of the relationship between inflammation and prevalent and incident MetS in patients with psychosis, including unpublished data from the Open Translational Science in Schizophrenia (OPTICS) Project, an open-science initiative between Janssen and the NIMH. This R03 application: 1) Has Aims congruent with NIMH's strategic focus on clinically useful biomarkers that predict change across the trajectory of illness, 2) Is a rigorously designed systematic review and meta-analysis using unpublished data from the OPTICS Project to investigate a novel potential biomarker that may identify—prior to treatment— patients with psychosis at heightened risk for incident adverse cardiometabolic effects of antipsychotics, and represents a “next-step” towards personalized medicine approaches for these patients, and 3) Supports the career transition of an L30 and K23 awardee to an R-series Investigator, consistent with the NIH's Next Generation Researchers Initiative.